Vanda Pharmaceuticals (VNDA) Interest & Investment Income (2010 - 2011)
Vanda Pharmaceuticals recorded quarterly Interest & Investment Income of $99000.0 in Q4 2011, down 6.6% quarter-over-quarter from $106000.0 in Q3 2011, and down 30.28% year-over-year from $142000.0 in Q4 2010.
Vanda Pharmaceuticals' Interest & Investment Income history runs 2 years deep, the most recent figure standing at $99000.0 for Q4 2011.
- In Q4 2011, Interest & Investment Income fell 30.28% year-over-year to $99000.0; the TTM figure through Dec 2011 stood at $468000.0 (changed N/A YoY), while the FY2011 annual figure was $461000.0, up 6.96% from the prior year.
- Interest & Investment Income came in at $99000.0 for Q4 2011 at Vanda Pharmaceuticals, down from $106000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $156000.0 in Q3 2010 to a low of $86000.0 in Q2 2010.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 99,000.00 |
| Sep 30, 2011 | 106,000.00 |
| Jun 30, 2011 | 121,000.00 |
| Dec 31, 2010 | 142,000.00 |
| Sep 30, 2010 | 156,000.00 |
| Jun 30, 2010 | 86,000.00 |